Evidences of Early Senescence in Multiple Myeloma Bone Marrow Mesenchymal Stromal Cells

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  André, Thibaud ^a   Meuleman, Nathalie ^a   Stamatopoulos, Basile ^a   De Bruyn, Cécile ^a   Pieters, Karlien ^a   Bron, Dominique ^a   Lagneaux, Laurence ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; BORTEZOMIB; CHEMOKINE; CYTOKINE; LENALIDOMIDE; PROTEIN P21; PROTEIN P53; THALIDOMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CELL ADHESION; CELL AGING; CELL CYCLE REGULATION; CELL FRACTIONATION; CELL MEMBRANE; CELL PROLIFERATION; CELL SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOMODULATION; MALE; MESENCHYMAL STEM CELL; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; PROTEIN EXPRESSION; SENESCENCE; TUMOR MICROENVIRONMENT; UPREGULATION;

ADULT; AGED; ANTIGENS, CD34; BETA-GALACTOSIDASE; BONE MARROW CELLS; CELL AGING; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; HEMATOPOIESIS; HUMANS; LEUKOCYTES; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; MULTIPLE MYELOMA; OSTEOBLASTS; RECURRENCE;

EID: 84875329801     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059756     Document Type: Article

References (66)

1. Palumbo A, Anderson K, (2011) Multiple myeloma. N Engl J Med 364: 1046-1060.
2. Rajkumar SV, (2011) Treatment of multiple myeloma. Nat Rev Clin Oncol 8: 479-491.
3. Kyle RA, Rajkumar SV, (2004) Multiple myeloma. N Engl J Med 351: 1860-1873.
4. Bataille R, Harousseau JL, (1997) Multiple myeloma. N Engl J Med 336: 1657-1664.
5. Greipp PR, San Miguel J, Durie BGM, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J, (2005) International staging system for multiple myeloma. J Clin Oncol 23: 3412-3420.
6. Anderson KC, Carrasco RD, (2011) Pathogenesis of myeloma. Annu Rev Pathol 6: 249-274.
7. Blade J, Rosinol L, Cibeira MT, de Larrea CF, (2008) Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia 22: 1651-1657.
8. Pasqualetti P, Casale R, (1997) Risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. Biomed Pharmacother 51: 74-78.
9. Brody H, (2011) Multiple myeloma. Nature 480: S33.
10. Podar K, Richardson PG, Hideshima T, Chauhan D, Anderson KC, (2007) The malignant clone and the bone-marrow environment. Best Pract Res Clin Haematol 20: 597-612.
11. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC, (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7: 585-598.
12. Caers J, Van Valckenborgh E, Menu E, Van Camp B, Vanderkerken K, (2008) Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment. Bull Cancer 95: 301-313.
13. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC, (1993) Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 82: 3712-3720.
14. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, et al. (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15: 1950-1961.
15. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J, (2002) Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 116: 278-290.
16. Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, et al. (2007) Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 21: 1079-1088.
17. Wallace SR, Oken MM, Lunetta KL, Panoskaltsis-Mortari A, Masellis AM, (2001) Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. Cancer 91: 1219-1230.
18. Garderet L, Mazurier C, Chapel A, Ernou I, Boutin L, (2007) Mesenchymal stem cell abnormalities in patients with multiple myeloma. Leuk Lymphoma 48: 2032-2041.
19. Barille-Nion S, Barlogie B, Bataille R, Bergsagel PL, Epstein J (2003) Advances in biology and therapy of multiple myeloma. Hematology Am Soc Hematol Educ Program 248-278.
20. Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, et al. (2006) Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 135: 688-692.
21. Najar M, Rouas R, Raicevic G, Boufker HI, Lewalle P, Meuleman N, Bron D, (2009) Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy 11: 570-583.
22. Tondreau T, Lagneaux L, Dejeneffe M, Delforge A, Massy M, (2004) Isolation of BM mesenchymal stem cells by plastic adhesion or negative selection: phenotype, proliferation kinetics and differentiation potential. Cytotherapy 6: 372-379.
23. De Bruyn C, Najar M, Raicevic G, Meuleman N, Pieters K, Stamatopoulos B, (2011) A rapid, simple, and reproducible method for the isolation of mesenchymal stromal cells from Wharton's jelly without enzymatic treatment. Stem Cells Dev 20: 547-557.
24. Dexter TM, Allen TD, Lajtha LG, (1977) Conditions controlling the proliferation of haemopoietic stem cells in vitro. J Cell Physiol 91: 335-344.
25. Huang DW, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
26. Huang DW, Sherman BT, Lempicki RA, (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1-13.
27. Wagner W, Horn P, Castoldi M, Diehlmann A, Bork S, Saffrich R, et al. (2008) Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS One 3: e2213.
28. Yew TL, Chiu FY, Tsai CC, Chen HL, Lee WP, Chen YJ, Chang MC, Hung SC, (2011) Knockdown of p21(Cip1/Waf1) enhances proliferation, the expression of stemness markers, and osteogenic potential in human mesenchymal stem cells. Aging Cell 10: 349-361.
29. Basak GW, Srivastava AS, Malhotra R, Carrier E, (2009) Multiple myeloma bone marrow niche. Curr Pharm Biotechnol 10: 345-346.
30. Arnulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne MN, Crinquette A, et al. (2007) Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 21: 158-163.
31. Todoerti K, Lisignoli G, Storti P, Agnelli L, Novara F, et al. (2010) Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease. Exp Hematol 38: 141-153.
32. Martinez-Jaramillo G, Vela-Ojeda J, Flores-Guzman P, Mayani H, (2011) In vitro growth of hematopoietic progenitors and stromal bone marrow cells from patients with multiple myeloma. Leuk Res 35: 250-255.
33. Xu X, Zhang X, Wang S, Qian H, Zhu W, Cao H, Wang M, Chen Y, Xu W, (2011) Isolation and comparison of mesenchymal stem-like cells from human gastric cancer and adjacent non-cancerous tissues. J Cancer Res Clin Oncol 137: 495-504.
34. Campisi J, (2005) Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 120: 513-522.
35. Garayoa M, Garcia JL, Santamaria C, Garcia-Gomez A, Blanco JF, Pandiella A, Hernandez JM, Sanchez-Guijo FM, del Canizo MC, Gutierrez NC, San Miguel JF, (2009) Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia 23: 1515-1527.
36. Giuliani N, Lisignoli G, Novara F, Storti P, Zaffaroni N, Villa R, et al. (2010) Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients. Leukemia 24: 1368-1370.
37. Coppe JP, Desprez PY, Krtolica A, Campisi J, (2010) The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 5: 99-118.
38. Raicevic G, Najar M, Pieters K, De Bruyn C, Meuleman N, Bron D, Toungouz M, Lagneaux L, (2012) Inflammation and Toll-Like Receptor Ligation Differentially Affect the Osteogenic Potential of Human Mesenchymal Stromal Cells Depending on Their Tissue Origin. Tissue Eng Part A 18(13-14): 1410-8.
39. Schellenberg A, Lin Q, Schuler H, Koch CM, Joussen S, (2011) Replicative senescence of mesenchymal stem cells causes DNA-methylation changes which correlate with repressive histone marks. Aging (Albany NY) 3: 873-888.
40. Li B, Shi M, Li J, Zhang H, Chen B, Chen L, Gao W, Giuliani N, Zhao RC, (2007) Elevated tumor necrosis factor-alpha suppresses TAZ expression and impairs osteogenic potential of Flk-1+ mesenchymal stem cells in patients with multiple myeloma. Stem Cells Dev 16: 921-930.
41. Li X, Ling W, Pennisi A, Khan S, Yaccoby S, (2009) Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability. Cancer Lett 284: 175-181.
42. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JDJ, (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349: 2483-2494.
43. Gunn WG, Conley A, Deininger L, Olson SD, Prockop DJ, Gregory CA, (2006) A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 24: 986-991.
44. Zhang CC, Lodish HF, (2008) Cytokines regulating hematopoietic stem cell function. Curr Opin Hematol 15: 307-311.
45. Hassan HT, Zander A, (1996) Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis. Acta Haematol 95: 257-262.
46. Patchen ML, MacVittie TJ, Williams JL, Schwartz GN, Souza LM, (1991) Administration of interleukin-6 stimulates multilineage hematopoiesis and accelerates recovery from radiation-induced hematopoietic depression. Blood 77: 472-480.
47. Zhang CC, Lodish HF, (2004) Insulin-like growth factor 2 expressed in a novel fetal liver cell population is a growth factor for hematopoietic stem cells. Blood 103: 2513-2521.
48. Fong CY, Gauthaman K, Cheyyatraivendran S, Lin HD, Biswas A, Bongso A, (2012) Human umbilical cord Wharton's jelly stem cells and its conditioned medium support hematopoietic stem cell expansion ex vivo. J Cell Biochem 113: 658-668.
49. Takeda K, Kaisho T, Yoshida N, Takeda J, Kishimoto T, Akira S, (1998) Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J Immunol 161: 4652-4660.
50. Yagi H, Soto-Gutierrez A, Parekkadan B, Kitagawa Y, Tompkins RG, et al. (2010) Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant 19: 667-679.
51. Feng Y, Wen J, Mike P, Choi DS, Eshoa C, Shi ZZ, Zu Y, Chang CC, (2010) Bone marrow stromal cells from myeloma patients support the growth of myeloma stem cells. Stem Cells Dev 19: 1289-1296.
52. Zlei M, Egert S, Wider D, Ihorst G, Wasch R, Engelhardt M, (2007) Characterization of in vitro growth of multiple myeloma cells. Exp Hematol 35: 1550-1561.
53. Zdzisinska B, Bojarska-Junak A, Dmoszynska A, Kandefer-Szerszen M, (2008) Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells. Arch Immunol Ther Exp (Warsz) 56: 207-221.
54. Raaijmakers MHGP, Mukherjee S, Guo S, Zhang S, Kobayashi T, et al. (2010) Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464: 852-857.
55. Hasskarl J, Ihorst G, De Pasquale D, Schrottner P, Zerweck A, Wasch R, Engelhardt M, (2011) Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma. Leuk Lymphoma 52: 247-259.
56. Mailankody S, Pfeiffer RM, Kristinsson SY, Korde N, Bjorkholm M, Goldin LR, Turesson I, Landgren O, (2011) Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood 118: 4086-4092.
57. McLean K, Gong Y, Choi Y, Deng N, Yang K, Bai S, Cabrera L, Keller E, et al. (2011) Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J Clin Invest 121: 3206-3219.
58. Ohuchida K, Mizumoto K, Murakami M, Qian LW, Sato N, Nagai E, et al. (2004) Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res 64: 3215-3222.
59. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449: 557-563.
60. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, (2003) Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102: 3837-3844.
61. Coppe JP, Patil CK, Rodier F, Krtolica A, Beausejour CM, Parrinello S,et al. 2010) A human-like senescence-associated secretory phenotype is conserved in mouse cells dependent on physiological oxygen. PLoS One 5: e9188.
62. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, et al. (2008) Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6: 2853-2868.
63. Lisanti MP, Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, Pestell RG, (2011) Accelerated aging in the tumor microenvironment: connecting aging, inflammation and cancer metabolism with personalized medicine. Cell Cycle 10: 2059-2063.
64. Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, (2007) Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 21: 1733-1738.
65. Ciavarella S, Grisendi G, Dominici M, Tucci M, Brunetti O, (2012) Dammacco (2012) In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells. Br J Haematol 157: 586-598.
66. Davies FE, Dring AM, Li C, Rawstron AC, Shammas MA, et al. (2003) Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 102: 4504-4511.